Globus Medical (GMED) Stock Forecast & Price Target
Globus Medical · NYSE
$80.62+2.37 (+3.03%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 12 firms covering Globus Medical, 10 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $80.00 to $123.00, a moderate spread. The average target of $101.83 sits 26% above the current $80.62. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 9 to 10 over recent months. On the fundamentals, the Street sees consensus EPS building from about $1.17 next quarter toward $5.15 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 ratings
Strong Buy
Strong Buy00%
Buy1083%
Hold217%
Sell00%
Strong Sell00%
Based on 12 analysts giving stock ratings to Globus Medical.
As of Jul, 10 of 12 firms rate GMED a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
GMED EPS & revenue forecast
EPS · NEXT QUARTER
$1.17
Range $1.11 – $1.22 · 14 analysts · -1% YoY
Next period, 14 analysts expect Globus Medical to earn $1.17 a share (range $1.11 – $1.22), versus $1.18 a year earlier. Full-year consensus is $4.74, growing to $5.15 the year after.
REVENUE · NEXT QUARTER
$796.6M
Range $781.2M – $807.8M · 14 analysts · +4% YoY
Revenue is expected to reach $796.6M (range $781.2M – $807.8M), +3.6% year-over-year. Full-year consensus is $3.2B, rising to $3.4B next year.
Top analysts covering Globus Medical
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GMED.
#1
William Plovanic
Canaccord Genuity · Rank #190
Buy
$90.00+11.6% to target
Overall win rate
36%
+ Follow
#2
David Saxon
Needham · Rank #264
Buy
$117.00+45.1% to target
Overall win rate
34%
+ Follow
#3
David Turkaly
JMP Securities · Rank #276
Hold
No targeton GMED
Overall win rate
31%
+ Follow
#4
Matt O'Brien
Piper Sandler · Rank #356
Buy
$100.00+24.0% to target
Overall win rate
25%
+ Follow
#5
Richard Newitter
Truist Securities
Buy
$100.00+24.0% to target
Coverage
—
+ Follow
GMED stock forecast FAQ
What is GMED's average 12-month price target?+
The 11 analysts with a live target average $101.83 for Globus Medical over the next 12 months, ranging from a $123.00 high to a $80.00 low.
Is GMED stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 12 analyst ratings, 10 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for GMED?+
The Street-high target is $123.00 (Barclays), and the Street-low is $80.00 (Stifel). The average of all 11 active targets is $101.83.
How many Wall Street analysts cover GMED?+
12 analysts have an active rating on Globus Medical, and 11 firms carry a live 12-month price target.
Who is the most accurate analyst covering GMED?+
Among analysts who currently cover GMED, William Plovanic of Canaccord Genuity has the strongest overall Quantellect track record (Rank #190). Their current call is Buy with a $90.00 target.
What is Globus Medical's projected EPS for next quarter?+
The consensus estimate is $1.17 per share (range $1.11 – $1.22) across 14 analysts. Full-year EPS is projected at $4.74, rising to $5.15 the following year.
How much revenue is Globus Medical expected to report next quarter?+
Consensus revenue is $796.6M (range $781.2M – $807.8M). Full-year revenue is projected at $3.2B, growing to $3.4B next year.
Have analysts been upgrading or downgrading GMED lately?+
As of Jul, 10 of 12 firms rate GMED a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GMED calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
